<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80634">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01942447</url>
  </required_header>
  <id_info>
    <org_study_id>UKT-FMT</org_study_id>
    <secondary_id>UKT</secondary_id>
    <nct_id>NCT01942447</nct_id>
  </id_info>
  <brief_title>Fecal Microbiota Transplantation in Recurrent or Refractory Clostridium Difficile Colitis</brief_title>
  <acronym>TOCSIN</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <authority>Germany: Ethikkommission Tuebingen</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The host gastrointestinal microbiota is significantly influenced by antibiotic treatment
      which might favor Clostridium difficile infection (CDI), a frequent cause of community- and
      hospital-acquired, potentially life-threatening diarrhoea. CDI is followed by recurrence in
      19-35% of patients despite adequate first line antimicrobial therapy. Currently there is no
      standardized therapy of recurrent or refractory CDI, but recent studies show remarkable
      effects of fecal microbiota transplantation (FMT).

      In the current project, we aim to ideally match host and donor for FMT success  in recurrent
      or refractory CDI. We will establish a clinical standard operating protocol for FMT, we will
      evaluate its safety and efficacy, and the patient acceptance and quality of life before and
      after FMT. We will analyse persistence of the donor microbiota within the recipient, define
      predictive clinical recipient and donor factors for FMT success and correlate them with
      microbial host and donor metagenomics.

      We hypothesize that our work will yield novel, individualized strategies for recurrent or
      refractory CDI. In perspective, our results may be expanded to treatment of other inflammory
      bowel diseases.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Resolution of diarrhea</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Resolution of diarrhea</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient acceptance</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Persitence of FMT</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Clostridium Difficile</condition>
  <condition>Clostridium Difficile Infection</condition>
  <arm_group>
    <arm_group_label>FMT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FMT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vancomycin</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FMT</intervention_name>
    <arm_group_label>FMT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <arm_group_label>Standard</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  recurrent or refractory CDI

          -  previous antimicrobial therapy includes at least on course of vancomycin 4x125 (or
             higher doses) for at least 7d

          -  CDI, defined as: 3 or more loose bowel movements/d AND (presence of C.diff. toxin in
             stools or toxin producing C. diff. strain) OR (endoscopic or histologic evidence of
             pseudomembraneous colitis)

        Exclusion Criteria:

          -  no informed consent

          -  no ability to provide informed consent

          -  immune suppression (continuous immune-suppressive drugs; steroids:
             prednisolone-equivalent &gt; 20 mg for 14d or longer)

          -  lack of appropriate donor

          -  pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Martin Goetz, Prof</last_name>
    <email>martin.goetz@med.uni-tuebingen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitaetsklinikum Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Goetz, Prof.</last_name>
      <email>martin.goetz@med.uni-tuebingen.de</email>
    </contact>
    <investigator>
      <last_name>Martin Goetz, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.med.uni-tuebingen.de/Zuweiser/Kliniken/Medizinische+Klinik/Innere+Medizin+I.html</url>
  </link>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 10, 2013</lastchanged_date>
  <firstreceived_date>September 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>Martin Goetz</investigator_full_name>
    <investigator_title>Univ.-Prof. Dr. med. Martin Goetz</investigator_title>
  </responsible_party>
  <keyword>Fecal microbiota transplantation</keyword>
  <keyword>microbiota</keyword>
  <keyword>clostridium difficile</keyword>
  <keyword>clostridium difficile infection</keyword>
  <keyword>Efficacy of FMT</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clostridium Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
